CATB-101 / CatenaBio - LARVOL DELTA

Dual-payload antibody drug conjugate targeting TROP2: Multi-Payload Conjugates™ targeting orthogonal mechanisms of cell killing (AACR 2026) - "Sacituzumab govitecan (SG), is approved as a 3rd line therapy in metastatic HER2 negative breast cancer...In head-to-head comparisons, CATB-101 outperforms T-DXd, SG and Dato-DXd with full tumor elimination at low doses... Advances have been made in the design of ADCs to expand to previously unaddressed populations. High patient relapse and the failure of recent mono-payload ADCs in late-stage trials indicate a need for next generation multi-payload conjugates. Catena's MPCs™ offer a next step in ADC design and allow for targeted delivery of multiple mechanisms of action with a single MPC™ while reducing off-target toxicity."

ADC • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR • HER-2 • TACSTD2 • TOP1

Dual-payload TROP2 targeted antibody drug conjugate: Multi-Payload Conjugates™ deliver orthogonal mechanisms of cell killing (SABCS 2025) - "Sacituzumab govitecan (SG), a TROP2 targeted ADC, is approved as a 3rd line therapy in locally advanced or metastatic HER2 negative breast cancer, and in combination with pembrolizumab, is likely to see approval in 1st line therapy for PD-L1 positive tumors...Our selective conjugation platform allows the attachment of distinct payloads targeting different mechanisms of action at three unique sites on antibody scaffolds. Catena's lead TROP2 targeting MPC, CATB-101, features an optimized combination and ratio of tubulin and Topo1 inhibitors...In head-to-head comparisons with T-DXd, SG and Dato-DXd, MPCs out-perform the current approved ADCs in breast cancer and demonstrate full tumor elimination at low mg/kg doses... While advances have been made in the design of ADCs to expand to previously unaddressed populations, high patient relapse and the failure of recent mono-payload ADCs in late-stage trials indicate a need for novel multi-payload conjugates. Catena's..."

IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Triple Negative Breast Cancer • HER-2 • TACSTD2